July 2021 $15 million placement completed to accelerate cancer diagnostic test development August 2021 Proof-of-concept achieved in feasibility studies demonstrating that a SubB2M-based test can detect a biomarker for ovarian cancer in patient samples July 2022 US-based contract sales team engaged to accelerate EXO-NET commercial roll-out September 2021 Dr Greg Rice appointed Chief Scientific Officer (CSO) to accelerate the commercial development of the company’s diagnostic tests November 2021 US patent issued for BARD1 technology, covering autoantibody test for lung cancer December 2021 Company changes its name fromBARD1 to INOVIQ Ltd, representing ‘intelligent innovation’ April 2022 US-based contract diagnostics organisation ResearchDx engaged to further the development and validation of INOVIQ’s SubB2Mbased tests in the USA January 2022 US patent issued for BARD1 technology, covering autoantibody tests for breast and ovarian cancer July 2021 University of Queensland researchers unveil promising results for a exosome-based blood test for ovarian cancer August 2021 Share Purchase Plan successfully completed with oversubscribed applications of $3.4m accepted July 2022 Grant of SubB2MU.S. patent December 2021 Chinese patent issued for BARD1 technology, covering autoantibody test for lung cancer July 2022 Grant of U.S. patent for hTERT April 2022 A Scientific Statement co-authored by INOVIQ’s Chief Scientific Officer, Dr Greg Rice, is published in scientific journal Endocrine Reviews July 2022 Positive SubB2M IHC results for Melanoma achieved May 2022 Australian patent is granted for SubB2M technology April 2022 INOVIQ and The University of Queensland (UQ) expand collaboration to develop a world-first exosome-based ovarian cancer screening test providing INOVIQ with exclusive option to licence intellectual property for commercialisation of diagnostic test 4 INOVIQ Limited 2022 Key Highlights
RkJQdWJsaXNoZXIy MjE2NDg3